Transparency Disclosure - EFPIA
Sandoz A/S as a Novartis company seeks to collaborate with Healthcare Professionals (HCPs) and Healthcare Organizations (HCOs) in the interest of patients. As an industry we make payments or ‘transfers of value’ to Healthcare Professionals and Organizations to compensate them for the time spent working with us.
In line with the European Federation of Pharmaceutical Industries and Associations (EFPIA) HCP/HCO Disclosure Code and its local transpositions, we are disclosing payments and other transfers of value.
Bringing greater transparency to this already well-regulated relationship builds understanding of this collaboration and addresses public concerns about interactions between the medical community and the pharmaceutical industry.
We believe that openly communicating payments and transfers of value related to these interactions helps foster trust with patients, HCPs, government officials and the public and supports our commitment to high ethical business standards.
Our Disclosure Reports
Methodological Note Sandoz Nordics 2022
Payment Disclosure Sandoz Denmark (Link to the Danish Medicines Agency)
Payment Disclosure Sandoz Sweden 2022 SE
Payment Disclosure Sandoz Sweden 2022
Methodological Note Sandoz Nordics 2021
Payment Disclosure Sandoz Norway 2021
Payment Disclosure Sandoz Finland 2021
Payment Disclosure Sandoz Sweden 2021
Payment Disclousure Sandoz Sweden 2021 SE
Methodological Note Sandoz Nordics 2020
Payment Disclosure Sandoz Sweden 2020
Payment Disclosure Sandoz Finland 2020
Payment Disclosure Sandoz Norway 2020
Methodological Note Sandoz Nordics 2019
Payment Disclosure Sandoz Finland 2019
Payment Disclosure Sandoz Norway 2019
Patient Organization Funding